Patents Examined by Svetlana M Ivanova
  • Patent number: 11510890
    Abstract: The present invention relates to a compound, in particular a meroterpenoid compound, or salt thereof, for use in the prevention and/or treatment of a neurological disorder in an individual. The compound of the invention can promote lactate secretion. A composition comprising the compound of the invention, and a food or food extract enriched with said compound or composition is also provided.
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: November 29, 2022
    Assignee: Societe des Produits Nestle S.A.
    Inventors: Denis Marcel Barron, Yann Ratinaud, Jonathan Thevenet, Andreas Christian Wiederkehr
  • Patent number: 11491166
    Abstract: Disclosed herein is a stable, ready-to-use liquid formulation comprising spironolactone and its method of use.
    Type: Grant
    Filed: December 4, 2020
    Date of Patent: November 8, 2022
    Assignee: CMP DEVELOPMENT LLC
    Inventors: Anthony Pipho, Michael Paul DeHart
  • Patent number: 11484532
    Abstract: Compounds and methods for modulating the activity of receptors are disclosed. Some of the compounds modulate the activity of glycine receptors. Certain embodiments of the compounds are useful for treatment of pain, treatment of opioid addiction, and/or reduction of side effects attributable to opioid use.
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: November 1, 2022
    Assignee: University of Pittsburgh—Of the Commonwealth Sysetem of Higher Education
    Inventors: Yan Xu, Pei Tang, Marta Megan Wells
  • Patent number: 11478471
    Abstract: Pharmaceuticals compositions comprising the 2S,4R, ketoconazole enantiomer or its pharmaceutically acceptable salts, hydrates, and solvates, that are substantially free of the 2R,4S ketoconazole enantiomer are useful to reduce cortisol synthesis and for the treatment of type 2 diabetes, hyperglycemia, obesity, insulin resistance, dyslipidemia, hyperlipidemia, hypertension, Metabolic Syndrome, and other diseases and conditions, including but not limited to Cushing's Syndrome, depression, and glaucoma.
    Type: Grant
    Filed: November 10, 2020
    Date of Patent: October 25, 2022
    Assignee: Strongbridge Dublin Limited
    Inventor: Per Marin
  • Patent number: 11471434
    Abstract: A first aspect of the invention relates to leucine, acetyl-leucine, or a pharmaceutically acceptable salt thereof, for use in treating or preventing a migraine, or one or more symptoms associated therewith. A second aspect of the invention relates to a method of treating or preventing a migraine, or one or more symptoms associated therewith, in a subject, said method comprising administering to the subject a therapeutically or prophylactically effective amount of leucine, acetyl-leucine, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: October 18, 2022
    Assignee: INTRABIO LTD.
    Inventors: Michael Strupp, Mallory Factor
  • Patent number: 11471432
    Abstract: The invention relates to a combination therapy for the prevention and/or treatment of immune-mediated chronic inflammatory and autoimmune diseases comprising a combination of one or more C3-C8 carboxylic acids, physiologically acceptable salts and/or esters thereof, and one or more fumaric acid esters and/or salts thereof. The combination being particularly useful in the treatment of psoriasis and multiple sclerosis.
    Type: Grant
    Filed: June 29, 2020
    Date of Patent: October 18, 2022
    Assignee: Flexopharm Brain GMBH & Co. KG
    Inventors: Ralf Gold, Aiden Haghikia, Ulrich Matthes
  • Patent number: 11464757
    Abstract: In various embodiments, the present invention provides compositions and methods for treating and/or preventing cardiovascular-related diseases in subject in need thereof.
    Type: Grant
    Filed: January 13, 2021
    Date of Patent: October 11, 2022
    Assignee: Amarin Pharmaceuticals Ireland Limited
    Inventors: Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni, Mehar Manku
  • Patent number: 11464720
    Abstract: This TRPA1 activity inhibitor contains a compound represented by formula (I) wherein R1, R2, R3 and R4 each independently represent a hydrogen atom or a methyl group, and R5, R6, R7 and R8 each independently represent a hydrogen atom, a methyl group or —O—R9—OH (in the formula, R9 represents an alkylene group optionally having a substituent group), provided that at least one group of R5, R6, R7 and R8 is —O—R9—OH.
    Type: Grant
    Filed: March 13, 2018
    Date of Patent: October 11, 2022
    Assignees: MANDOM CORPORATION, TAKASAGO INTERNATIONAL CORPORATION
    Inventors: Masayuki Takaishi, Fumitaka Fujita, Hironori Shimizu, Shu Sakuyama, Kenya Ishida, Kenji Maruyama
  • Patent number: 11464759
    Abstract: The present invention relates to 5-HT6 receptor antagonists for the treatment of Alzheimer's disease where the Alzheimer's disease patient carries one or two ApoE4 alleles comprising administering an effective dose of a 5-HT6 receptor antagonist to improve or augment the effect of an acetylcholinesterase inhibitor.
    Type: Grant
    Filed: May 23, 2018
    Date of Patent: October 11, 2022
    Assignee: H. Lundbeck A/S
    Inventor: Kristian Windfeld
  • Patent number: 11458148
    Abstract: Methods and compositions that can be used to modulate the activity of furin in a subject are disclosed herein. In some embodiments, the methods include administering a pharmaceutical composition including a protease inhibitor. In some embodiments, the protease inhibitor inhibits furin activity by binding to the catalytic site, the allosteric site, or both.
    Type: Grant
    Filed: February 21, 2017
    Date of Patent: October 4, 2022
    Assignee: Brigham Young University
    Inventors: Richard K. Watt, Chad Hancock
  • Patent number: 11446278
    Abstract: A topical composition includes a cannabinoid, a terpenoid, and a skin penetration system that includes dimethyl sulfoxide (DMSO) and at least one compatibilizer. The composition may be in the form of an emulsion that further contains water and at least one fatty component. The composition can be used to reduce or eliminate pain by topical application to an affected region of the body. The composition provides localized pain relief by providing a focused quantity of cannabinoid in the region of the pain instead of distributing the cannabinoid systemically and/or delivering it to the brain or central nervous system.
    Type: Grant
    Filed: August 20, 2021
    Date of Patent: September 20, 2022
    Assignee: TECH SWERVE LLC
    Inventor: John M. Guynn
  • Patent number: 11439607
    Abstract: A method is disclosed of treating pain with senicapoc, a potent Ca2+-activated K+ channel, KCa3.1 antagonist in CNS-resident microglia. Senicapoc is shown to cause in a decrease of IL-1? and NO release from microglia cells vivo and in vitro. Because of contribution of KCa3.1 to neuropathological processes, senicapoc is useful in the treatment of chronic, neuropathic, visceral, and inflammatory pain and the reversal of tactile allodynia.
    Type: Grant
    Filed: October 23, 2017
    Date of Patent: September 13, 2022
    Assignee: Paracelsus Neuroscience I, LLC
    Inventors: Roland Staal, Thomas Möller
  • Patent number: 11439630
    Abstract: The present invention relates to compositions comprising an antiemetic, particularly including 5-HT3 antagonist and/or NK-1 antagonist antiemetics, in combination with a choline esterase inhibitor such as an acetylcholine esterase inhibitor and/or a butyrylcholine esterase inhibitor, and methods of using the composition to provide improved protection of subjects at risk of organophosphorus poisoning, or, for the treatment, prevention, or alleviation/reduction of toxicity from an organophosphorus compound, by enabling the use of a highly protective daily dose of the choline esterase inhibitor without the typical adverse effects.
    Type: Grant
    Filed: June 19, 2018
    Date of Patent: September 13, 2022
    Inventor: Kathleen E. Clarence-Smith
  • Patent number: 11439618
    Abstract: In various embodiments, the present invention provides compositions and methods for treating and/or preventing cardiovascular-related diseases in subject in need thereof.
    Type: Grant
    Filed: January 13, 2021
    Date of Patent: September 13, 2022
    Assignee: Amarin Pharmaceuticals Ireland Limited
    Inventors: Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni, Mehar Manku
  • Patent number: 11439616
    Abstract: Compositions and methods of treating anxiety or stress in an animal are disclosed. Compositions and methods of reducing or preventing elevated levels of 4-EPS are disclosed. Compositions and methods for promoting growth of beneficial microbes in an animal's microbiome and inhibiting growth of non-beneficial microbes are disclosed. The methods comprise administering to the animal an effective amount of n-3 fatty acids, antioxidants, insoluble fiber and soluble fiber in an effective ratio of insoluble fiber and soluble fiber. Compositions comprise effective amounts of n-3 fatty acids, antioxidants, insoluble fiber and soluble fiber in an effective ratio of insoluble fiber and soluble fiber.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: September 13, 2022
    Assignee: Hill's Pet Nutrition, Inc.
    Inventors: Eden Ephraim, Dennis Jewell
  • Patent number: 11413264
    Abstract: The present invention relates to carbamoyl phenylalaninol analogs and methods of using the same to treat disorders.
    Type: Grant
    Filed: July 31, 2018
    Date of Patent: August 16, 2022
    Assignee: Jazz Pharmaceuticals Ireland Limited
    Inventor: Fionn Hurley
  • Patent number: 11395828
    Abstract: Disclosed herein is a stable, ready-to-use liquid formulation comprising spironolactone and its method of use.
    Type: Grant
    Filed: July 23, 2021
    Date of Patent: July 26, 2022
    Assignee: CMP DEVELOPMENT LLC
    Inventors: Anthony Pipho, Michael Paul DeHart
  • Patent number: 11389461
    Abstract: Disclosed herein is a stable, ready-to-use liquid formulation comprising spironolactone and its method of use.
    Type: Grant
    Filed: July 23, 2021
    Date of Patent: July 19, 2022
    Assignee: CMP DEVELOPMENT LLC
    Inventors: Anthony Pipho, Michael Paul DeHart
  • Patent number: 11389411
    Abstract: The present disclosure relates to a pharmaceutical composition for suppressing cancer metastasis containing, as an active ingredient, an activator compound of the cancer metastasis inhibitor Nm23, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof. The compound according to the present disclosure may suppress the metastasis of cancer cells by promoting the activity of Nm23 associated with cancer metastasis, and thus may be useful as a pharmaceutical composition for suppressing cancer metastasis.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: July 19, 2022
    Assignee: EWHA UNIVERSITY—INDUSTRY COLLABORATION FOUNDATION
    Inventors: Kong Joo Lee, Hee-Yoon Lee, Je Jin Lee, Eun-Kyoung Seo, Eun Sun Lee, Hwang Suk Kim, Hongsoo Lee
  • Patent number: 11369585
    Abstract: Provided herein are compositions, methods, systems and/or kits for preventing and/or treating neoplasms using at least one of quercetin, sodium phenyl butyrate and epigallocatechin-3-gallate in combination with one or more anti-cancer agents. The compositions, methods, systems and/or kits are used to prevent and/or treat neoplasms that are resistant to the one or more anti-cancer agents when administered alone.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: June 28, 2022
    Assignee: RESEARCH CANCER INSTITUTE OF AMERICA
    Inventor: Mohammed Amin Nezami